articleNature MedicineFeb 6, 2024HYBRID OA

MYC targeting by OMO-103 in solid tumors: a phase 1 trial

EGElena GarraldaMBMarie-Ève BeaulieuVMVíctor MorenoSCSílvia Casacuberta‐SerraSMSandra Martínez-Martín

Vall d'Hebron Institute of Oncology · Hospital Universitario Fundación Jiménez Díaz · +5 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Abstract Among the ‘most wanted’ targets in cancer therapy is the oncogene MYC, which coordinates key transcriptional programs in tumor development and maintenance. It has, however, long been considered undruggable. OMO-103 is a MYC inhibitor consisting of a 91-amino acid miniprotein. Here we present results from a phase 1 study of OMO-103 in advanced solid tumors, established to examine safety and tolerability as primary outcomes and pharmacokinetics, recommended phase 2 dose and preliminary signs of activity as secondary ones. A classical 3 + 3 design was used for dose escalation of weekly intravenous, single-agent OMO-103 administration in 21-day cycles, encompassing six dose levels (DLs). A total of 22…

Citation impact

165
total citations
FWCI
61.67
Percentile
100%
References
50
Citations per year

Authors

21

Topics & keywords

Topics
Keywords
  • Tolerability
  • Pharmacokinetics
  • Medicine
  • Pharmacodynamics
  • Response Evaluation Criteria in Solid Tumors
  • Clinical endpoint
  • Adverse effect
  • Toxicity
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding